SAB Biotherapeutics is trading at $3.20, up 9.22%, as the cause of the October 6 after-hours rise remains unclear. - The latest company release, dated October 1, announced a planned SAB-142 presentation; no October 6 announcement appears in the company’s news-release listing. - Major indexes rose during the October 6 session, but that broad-market strength alone does not explain the after-hours move. - Available evidence does not establish a direct cause.